Results of Treatment with Vixova® in
Prostatodynia and Chronic Prostatitis


The results of treatment in patients with symptoms of chronic prostatitis are often disappointing. This is partly due to controversy regarding the etiology and clinical significance of the different forms of the benign painful prostate (18), and in particular, a failure to use the diagnostic criteria and methods necessary for the differential diagnosis of the various forms of prostatic disease. However, even if a precise classification in chronic bacterial or non-bacterial prostatitis and prostatodynia has been reached, there is no treatment which will guarantee a lasting cure and many patients suffer for years or even decades from persisting symptoms (38).

Clinical investigations with Vixova® have provided evidence of symptomatic improvement in benign forms of prostatic disease (4,5,13,14,19). Here we report the results of a prospective study carried out in 90 patients to investigate the efficacy of Vixova® in respect to voiding dysfunction and inflammation in chronic prostatitis syndromes... read more




Effect of Pollexia on Experimental
Nonbacterial Prostatitis in Rats


The treatment for chronic nonbacterial prostatitis (NBP) has not been established. Pollexia pollen extract (ref. CN-009) is reported to have therapeutic effects for NBP. The effects and mechanisms of CN-009 were investigated. Pollexia consists of a water soluble fraction (PolliAQ) and fat-soluble fraction (PolliLIP).

Ten-month-old rats were used with administration of estradiol after castration, which were similar to human NBP histologically. Since CN-009 consists of PolliAq and PolliLip, these extracts were administered, respectively. The prostate was evaluated histopathologically including glandular damage (epithelial score), stromal ratio and immunohistochemical assays for epithelial function (PAP), stromal evaluation (Vimentin), cell proliferation (PCNA) and apoptosis (deoxyuridine triphosphate biotin nick end-labeling (TUNEL)) ... read more




Efficacy of Pollexia Administration for Infertile
Males Associated with Asymptomatic Pyospermia


The cases, that white blood cell is significantly higher in semen, accounts for 16 ~ 17% of male infertility patients. Interestingly, it was common that no bacterial finding is presented in these cases, using standardized bacterial test, PCR methods for Chlamydia trachomatis (C. trachomatis), and semi-quantitative analysis for Urea plasma urealyticum (U. urealyticum). Although these cases are classified in nonbacterial chronic prostatitis, it has been generally recognized to be associated with male infertility. In present study, we reported that administration of Pollexia reduce PMN-elastase activity and to improve seminal findings in semen for 17 male infertility patients with no bacterial finding in semen ... read more




Statements herein have not been reviewed by the Food and Drug Administration
Not intended to treat, cure, prevent or diagnose any disease




has been shown to help alleviate the following symptoms:

Excessive urges to urinate, including during the night.

Pain associated with prostate inflammation or enlargement.

Blood in urine.

Lack of seminal fluid production.




Copyright 2013 VIXOVA®